Agios Pharmaceuticals Stock Earnings Reports

Agios reported strong Q1 2026 execution, driven by the U.S. commercial launch of AQVESME in thalassemia and advancement of its PK activation franchise. Key financials: $20.7M in net revenues (138% YoY growth) with $18.8M from the U.S., R&D spend of $81M and SG&A of $48M, and over $1 billion in cash and marketable securities. Management reiterated that 2026 operating expenses are expected to be approximately flat versus 2025. Commercially, AQVESME REMS went live late January and early demand is encouraging with 242 prescriptions written by REMS-certified physicians as of March 31; company cautions early prescriptions reflect highly motivated patients and are not necessarily a steady run rate. Regulatory and R&D catalysts: Agios plans to submit an sNDA for mitapivat in sickle cell disease in Q2 under the accelerated approval pathway and is advancing confirmatory trial design discussions with the FDA. Mid‑ and long‑term pipeline milestones include Phase II tebapivat top-line readouts in lower‑risk MDS (H1 2026) and sickle cell disease (H2 2026), pediatric mitapivat trials in thalassemia, and other early-stage progress. Management emphasized a disciplined capital allocation approach focused on maximizing the AQVESME launch, managing operating expenses, and selectively expanding the pipeline.